Background: Adherence to intravenous chemotherapy offers survival and recurrence-free benefits for women diagnosed with early-stage breast cancer.
evidence of factors that may be potentially modified with interventions at the clinical setting. Implications for Practice: The findings can be used to spearhead future intervention studies that improve treatment decision making to chemotherapy adherence. n Background Adherence is important for women with breast cancer because it is a primary determinant of treatment effectiveness and optimum clinical benefit. Adherence is described as the extent to which an individual's behavior coincides with medical health advice. 1, 2 Racial differences exist for adherence in women with breast cancer who initiate and complete chemotherapy. African American women are more likely to be diagnosed and treated at a later stage of breast cancer than white women are because of delays in the diagnosis and initiation of treatment. 3Y5 Evidence also reveals racial disparities in the receipt of chemotherapy where African American women are less likely to receive chemotherapy treatment when compared with their white counterparts after a diagnosis of a stage 1a or higher hormone receptorYnegative breast tumor (67% vs 78%; P G .01). 6 However, the extent to which racial differences exist in adherence to intravenous chemotherapy is inconsistent and largely understudied.
Nonadherence to breast cancer treatments and treatment delays have been purported to partially explain worse breast cancer outcomes in African American women. 6, 7 However, it is important to note that these findings conflict with other studies where no significant differences between races were found to chemotherapy adherence rates. 8Y11 Inconsistencies in the relationship between race and chemotherapy adherence described in the literature indicate a need for more research to establish the role that race plays in chemotherapy adherence. Furthermore, the frequency, amount, and type of chemotherapy treatment are significantly different for early-and advanced-stage breast cancer, which can potentially cause a different decision-making process of risks and benefits seen in women with a more terminal diagnosis. Survival for early-stage breast cancer can be as high as 98%, within all races, because of the advancement in the treatment and management of early-stage breast cancer. 12 This recognition is important because it suggests that breast cancer survival disparities can be decreased through clinical interventions that increase adherence to treatment. This information is crucial for the development and testing of population-specific interventions that have the potential for addressing disparities in breast cancer treatment adherence and survival rates between African Americans and whites. Thus, the purposes of this study were to examine the variables that influence the decision to adhere to chemotherapy in a sample of African American and white women and to identify other relevant factors that may be associated with chemotherapy adherence in a sample of women with early-stage breast cancer.
Outcomes of adherence may include decrease in healthcare costs; decrease in disease exacerbations, crisis, or relapse; increase in patient quality; and preservation of life. 2, 13, 14 These benefits are not achievable if the patient does not adhere to medication or treatment. Adherence to intravenous chemotherapy for primary breast cancer is significantly associated with improved outcomes, when indicated, and offers greater survival and lower recurrence. 15, 16 An early systematic review of 133 randomized trials showed highly significant reduction in the annual rate of recurrence and death rates as a result of intravenous chemotherapy. 17 An overview of 18 000 women provided statistically definitive evidence that some form of chemotherapy can affect survival and recurrence, with an odds reduction of 21% for recurrence and 11% for mortality. This review demonstrated that the effect of chemotherapy on annual death rates after 5 years was highly significant, with a 28% reduction in recurrence rates and 16% reduction in mortality rates in the first 5 years. 17 To receive maximum benefits from adjuvant treatment, patients must adhere to chemotherapy treatment regimens. Early studies found that patients receiving less than 85% of total intravenous chemotherapy had a poorer clinical course than those receiving complete therapy. 15 A significant reduction in the 5-year relapse-free survival was seen in women with stage II breast cancer on intravenous chemotherapy who received less than 65% of the planned drug dose. 15 However, even when faced with a potentially life-threatening illness such as breast cancer, it cannot be assumed that the patient will adhere to intravenous chemotherapy. An early study found that 21% of the patients actually received more than 85% of the prescribed chemotherapy dose, 34% received 66% to 84% of the prescribed dose, and 45% received less than 65% of the dose prescribed. 18 There is a growth of literature that examines the role that race plays in predicting adherence to cancer therapy, 7, 11, 19 but these studies fail to examine or adjust for socioeconomic status (SES). However, it is important to note that many factors that determine SES are closely related to race. Minority groups make up most of the lower SES in America, so it is hard to tease out the effects of poverty from the effects of race, which may contribute to inconsistences in racial differences in adherence. For example, a study of 51 participants with early-stage breast cancer found that nonadherent patients were of a significantly lower SES, but the study did not report findings based on racial differences. 10 However, Hershman et al 7 found that African American women were more likely than white women to terminate intravenous chemotherapy treatment prematurely and were twice as likely to die as white women. Only 68% of African American patients, compared with 76% of white patients, completed all prescribed cycles of intravenous chemotherapy. Of the 270 white women in the study, 93% were still living 5 years after diagnosis, and of the 202 African American women, 81% were living 5 years after diagnosis. 7 This study was the first study to find an association between early termination of chemotherapy and racial disparities in breast cancer outcomes. The current study will further elucidate the role of sociodemographic, social, and behavioral factors on chemotherapy adherence in African American and white women with breast cancer.
Theoretical Framework
The study used an adaptation of the Health Decisions Model (HDM) for the conceptual basis for the study. The HDM is a revised version of the Health Belief Model, where it incorporates strengths of the Health Belief Model and modifying factors of patient preferences to provide various predictors of adherence. 20 The HDM consists of the following 6 key interrelated components that predict the health decision to adherence: sociodemographic, social interaction, experience, knowledge, general and specific health beliefs, and patient preferences.
The HDM provides the most appropriate and comprehensive framework to explore the predictors that best influence the decision to adhere to chemotherapy in women with breast cancer. For the purpose of this study, which is based on a sound review of the literature, sociodemographic, social interaction, knowledge, personal experience, and specific health beliefs were used in the study as the best predictors of adherence to chemotherapy. These 5 factors have been identified in the literature as predictors of cancer treatment and general medical adherence in various populations. Based on the HDM, the roles of sociodemographic factors (age, race, and access to care), social interaction factors (support mechanisms, ie, social support and religious coping), cancer experience (chemotherapy side effects and depression), breast cancer knowledge, and health beliefs (perceived susceptibility, severity, motivation, benefits and barriers of the disease and cancer fatalism) were examined as predictors of treatment decision making ( Figure) . 20 n Methods
Sample Recruitment
The sample size for this study was estimated using the Power Analysis and Sample Size statistical software for calculation. 21 Because the most statistically complex analysis that will be used in this study is multiple linear regressions, sample size was calculated using this statistical procedure. It was calculated that a sample size of 120 is needed to achieve 80% power to detect an R 2 of 0.10 attributed to 6 independent variable(s) using an F test with a significance level (!) of .05. A preliminary analysis of the data revealed a rather homogeneous sample with regard to adherence. A dominantly adherent group lacked the variation needed to compare differences between those who continued or discontinued chemotherapy. The preliminary analysis revealed that a sample size of n = 90 would produce an effect size of 0.299, whereas a sample of n = 120 would produce an effect size of 0.258. Because of the small variation between the effect size of a sample of 90 participants and 120 participants, recruitment efforts ended at 99 participants.
The study enrolled 48 white and 51 African American women diagnosed with early-stage breast cancer whose ages ranged between 26 and 86 years. Additional sample characteristics are presented in Table 1 . Early-stage breast cancer was defined as having a primary diagnosis of Stage I, II, or IIIa breast cancer. Recruitment sites that served low, middle, and/or high socioeconomic populations were targeted to ensure the availability of a heterogeneous sample. The sample was recruited from a large public hospital and a private academic hospital in the metropolitan Atlanta, Georgia area. Eligible participants volunteered to participate in the study. At the completion of the study, each participant was given a $10 gift card to a local grocery store for compensation of her time. Approval from a university's institutional review board and from the hospital research oversight committee for the clinic providing care was granted for the study.
Sample Inclusion/Exclusion Criteria
Inclusion criteria for participation were as follows: (1) selfreported African American/black or white woman; (2) diagnosed with early-stage (I, II, or IIIa) breast cancer; (3) completed 2 or fewer chemotherapy treatments; (4) able to read, write, and speak English; (5) initial and primary diagnosis of breast cancer documented in the medical charts; (6) recommended to receive an intravenous nonhormonal chemotherapy regimen for treatment; (7) provided voluntary consent to participate in the study; and (8) older than 21 years. Exclusion criteria for the study were as follows: (1) advanced-stage breast cancer (stage IIIb or IV), (2) chart documented of a major mental disorder, and (3) unable to read or write English. The frequency, amount, and type of chemotherapy treatment are different for early-and advancedstage breast cancer; these facts can potentially cause a difference in the decision-making process in women with a terminal diagnosis. Thus, the study included only women with a diagnosis of earlystage breast cancer as documented in her medical charts. All participants were requested to read and speak English in order to read, comprehend, and complete the questionnaires. Women treated with hormonal and self-administered oral chemotherapy were excluded because those treatments produce different costs and benefits to patients and may produce different predictors of treatment adherence. The study excluded women with mental disorders, to control for the risk of nonadherence due to poor mental health or lack of understanding of the study or her recommended treatment.
Measures

ADHERENCE
The outcome of interest was nonadherence to intravenous chemotherapy among African American and white women with early-stage breast cancer. A medical chart review was used to measure chemotherapy treatment adherence. A patient's missed appointment due to not showing up for an appointment, cancellation, or refusal of chemotherapy was documented in her medical records. Because previous studies found that patients receiving less than 85% of total chemotherapy had a poorer clinical course than did those receiving complete therapy, the original measure for adherence was based on a cutoff point of 85%. However, preliminary analysis of the data revealed a generally highly adherent sample, so the cutoff point was changed from those who were 100% adherent to chemotherapy to those who were less than 100% adherent. The reclassification was done to allow for adequate statistical analysis. Adherence was calculated by dividing the number of prescribed chemotherapy sessions by the number of appointments attended. Adherence was dichotomized as a yes or no variable where patients who attended 100% of their chemotherapy sessions were considered adherent (yes) and those completing less than 100% were considered nonadherent (no).
A second measure of adherence in this study was ''days from diagnosis to treatment.'' This was a proxy measure for adherence to treatment recommendations and to explore the length of time that lapsed for the woman to initiate recommended treatment. ''Days from diagnosis to treatment'' was measured by the number of days from the pathology-reported diagnosis of early-stage breast cancer to the initiation of cancer treatment (either surgery or chemotherapy) as documented in the medical chart.
SOCIODEMOGRAPHIC FACTORS
A demographic questionnaire was compiled by the principal investigator to collect demographic information from each subject, including age, race, education, combined household income, living arrangements, employment, stage of disease at diagnosis, type of health insurance, and usual transportation to appointments. Access to health insurance served as an indicator for SES, where subjects were placed into lower or working/middle class based on health insurance coverage. Participants with no health insurance coverage or with Medicaid were categorized as lower socioeconomic class. Those with private insurance or Medicare coverage were considered working/middle socioeconomic class.
SOCIAL SUPPORT
The Norbeck Social Support Questionnaire (NSSQ) was used to measure the perceived social support of the participants. 22 This instrument measures the types (affect, affirmation, and aid) and sources of social support through a 6-item and 3-situationspecific-item questionnaire using a 5-point rating scale from 0 (not at all) to 4 (a great deal). Because the NSSQ is not a summative-type instrument, Pearson correlations among the items and subscales were calculated to test internal consistency reliability. 22 Each of the 2 items for each subscale was highly correlated: affect, 0.97; affirmation, 0.96; and aid, 0.89. The test-retest correlations were 0.89 for affect, 0.88 for affirmation, and 0.86 for aid. Validity of the NSSQ was supported by concurrent and construct validity and the response bias of social desirability, which was ruled out. 23 Concurrent validity was tested with the Social Support Questionnaire, developed by Cohen and Lazarus. 24 The affirmation and affect scales of the NSSQ were moderately associated with the Social Support Questionnaire measure of informational support (r = 0.33) and emotional support (r = 0.51), respectively. 23 Construct validity was assessed using the Fundamental Interpersonal Relations Orientation measure. 25 Construct validity was demonstrated by significant associations between Fundamental Interpersonal Relations Orientation's need for inclusion and affection scales and NSSQ's functional subscales (r = 0.18Y0.27) and most of the NSSQ's network scales (r = 0.17Y0.23). 23 
RELIGIOUS COPING
The Pargament Religious Coping Scale, known as the RCOPE, 26 measures the ability to adapt to a life-changing event through the belief in a higher being and a range of religious coping strategies. This instrument is a 63-item questionnaire that measures both helpful and harmful religious coping methods. 26 Respondents are asked to reflect on the role that religion played as a form of coping during a specified event, such as chemotherapy sessions for the women in this study. Each respondent is asked to answer each question on the extent to which there is agreement with each statement using a Likert scale of 1 (not at all) to 4 (a great deal). Positive religious coping subscales (eg, spiritual support, benevolent religious reframing, collaborative religious coping, congregational support) range from 3 to 12, and the overall positive religious coping scale ranges from 36 (low) to 144 (high). Questions that constituted the negative religious coping subscales (eg, spiritual discontent, punitive religious reframing, self-directing religious coping, congregational discontent) range from 3 to 12, where the overall negative religious coping score ranges from 27 (low) to 108 (high). If the respondent is not religious, he/she is asked to substitute ''religion'' with ''spirituality'' and ''God'' with a ''higher being or force'' or to simply mark ''not at all'' if neither applied. 26 Factor analysis largely validated the conceptualization and the construction of the subscales and provided evidence of high internal consistency and incremental validity. All but 3 subscales (Reappraisal of God's Power, Marking Religious Boundaries, and Interpersonal Religious Discontent) had ! values of .65 or greater, and 7 subscales had ! values of .80 or greater for internal consistency subscales, confirming generally high reliability estimates. 26 
KNOWLEDGE
The participant's understanding of information relevant to the breast cancer diagnosis, including the risks, treatment options, and adverse effects that encompass the disease, was measured by the Comprehensive Breast Cancer Related Knowledge Test. 29 This scale is a 20-question true-false scale consisting of 2 subscales (general knowledge and curability) that assesses the knowledge of risk factors for breast cancer, symptoms of breast cancer, adverse effects of treatment, treatment efficacy, and methods of treatment. Correct answers were summed to produce a score that ranged from 0 to 12 for the general knowledge subscale and 0 to 8 for the curability subscale and an overall score ranging from 0 to 20. The internal consistency reliability for the posttested general knowledge subscale was .60 and for the curability subscale was .62, which is acceptable. The overall ! coefficient was .71. 29 
ADVERSE EFFECTS
The Memorial Symptom Assessment Scale Short Form (MSAS-SF) 30 was used to measure the participant's symptoms experienced during chemotherapy treatments. The MSAS-SF is an abbreviated version of the Memorial Symptom Assessment Scale developed to provide multidimensional information about common symptoms experienced in oncology populations. 30 The MSAS-SF instrument captures 28 prevalent symptoms of cancer therapies and assesses the patient's rated severity, frequency, and distress associated with the symptoms. The respondent is asked to mark the experiences he/she experienced during chemotherapy and then rate how bothersome or distressful the symptom was. Distress is rated on a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). Psychometric properties of the scale consisted of a Cronbach's ! coefficient that ranged from .80 to .87 for each subset of symptoms. The 1-day test-retest coefficient ranged from 0.86 to 0.94 and the 1-week test-retest ranged from 0.40 to 0.84. 30 The MSAS-SF subscales were assessed against the subscales of the Functional Assessment Cancer Therapy 31 to determine criterion validity. Correlation coefficients between the MSAS-SF and Functional Assessment Cancer Therapy subscales ranged from j0.74 to j0.68. 30 
DEPRESSION
Depression was measured by the Center for Epidemiologic StudiesYDepression Scale (CES-D). 32 This instrument is a 20-item self-report scale designed to survey 6 components of depression: depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of appetite, and sleep disturbance. Respondents indicate on a 4-point scale (0 = rarely or none at all, 3 = most or all of the time) how often within the last week they experienced each symptom. The scores for the 20 items are added and result in an overall score that ranges from 0 to 60. It is important to note that the CES-D is not a diagnostic tool and is only a measure of depressive symptomology where a score equals or greater than 16 is indicative of positive symptomology over the past week. Respondents who indicated high scores on the CES-D had their primary care provider notified for further evaluation.
Construct validity was evaluated in sample of women diagnosed with breast cancer by comparing the CES-D with the Profile of Mood State Fatigue Scale, 33 the State version of the State-Trait Anxiety Inventory, 34 and the Mental Health Summary Scale from the Short-Form 36 Health Survey (Vitality scale). 35 Construct validity was demonstrated by moderate to high correlations with measures of the Profile of Mood State (r = 0.66), State-Trait Anxiety Inventory (r = 0.77), and the Short-Form 36 Health Survey Vitality scale (r = j0.65). 32 The CES-D was found to have good internal consistency, with ! coefficients greater than .85 in a group of women with breast cancer as well as adequate test-retest reliability. 32 
HEALTH BELIEFS
The Champion's Health Belief Model Scale (CHBMS) 36 measures 5 concepts of the Health Belief Model: perceived susceptibility, perceived seriousness, perceived benefit, perceived barriers, and motivation. Each respondent is asked to rate using a 5-point Likert scale of 1 (strongly disagree) to 5 (strongly disagree) how much she agrees or disagrees with each statement. The instrument subscales assess beliefs related to susceptibility to breast cancer before diagnosis, seriousness of her breast cancer diagnosis, benefits of chemotherapy treatments, suspected barriers to chemotherapy treatments, and motivation for good health.
The test-retest correlations ranged from 0.47 to 0.86. 36 Factor analysis of the measure revealed statistical evidence for the independence of constructs. Principal components factor analysis for all items ranged from 0.36 to 0.75. Internal consistency of the factors ranged from 0.36 to 0.78. Cronbach's ! reliability coefficients for subscales ranged from .80 to .93. 36 A multiple regression analysis of the subscales revealed a multiple R of 0.51, with 26% of variance accounted for in the model, which also demonstrates construct validity. 36 
CANCER FATALISM
The Powe Fatalism Inventory (PFI) 37 was used to measure the fatalistic belief that death is inevitable with breast cancer. Items address fear, predetermination, pessimism, and inevitability of death through 15 yes or no questions. Yes responses are summated to produce a PFI score. Scores ranging from 0 to 8 denote low fatalism attitudes and scores of 9 to 15 denote high fatalism.
In a sample of African American women, the PFI has a reported internal consistency reliability ranging from .84 to .87. 37 Validity and factor analysis of the PFI is acceptable. 37 Factor analysis resulted in all items loading on 1 factor. Fourteen of the items revealed Eigenvalues greater than 0.30. The coefficient ! for internal consistency reliability was .87.
Data Collection
To help alleviate the possible burden of completing several questionnaires among this population, data collection consisted of 2 time points: time point 1 (T1), at enrollment, and time point 2 (T2), at the end of the participant's chemotherapy sessions. Upon enrollment in the study or at the initiation of intravenous chemotherapy (T1), 4 questionnaires were administered: (1) demographics measure, (2) CES-D, (3) PFI, and (4) CHBMS. The timing of administration of these questionnaires was considered as the appropriate baseline information for each participant. The PFI and CHBMS were used to determine attitudes, beliefs, and feelings about breast cancer that existed at initiation of the chemotherapy treatment regimen that may predict the participant's decision to adhere or discontinue chemotherapy. Depression scores were also obtained at baseline and T2 to detect for change in mood.
The duration of recommended chemotherapy for early breast cancer varied between women, ranging from 1 to 6 months. The second time point was at the end of the prescribed intravenous chemotherapy therapy (T2), and the following 5 questionnaires were administered: (1) RCOPE, (2) MSAS-SF, (3) CES-D, (4) NSSQ, and (5) the Breast Cancer Related Knowledge Measure. The RCOPE was administered at T2 to capture social support that the participant used throughout the entire (before and during) chemotherapy regimen. The MSAS-SF was used to identify symptoms the woman experienced during chemotherapy treatment. The CES-D was used at this time point to capture depression that may have occurred during chemotherapy. The knowledge measure was administered at T2 to measure the amount of knowledge the participant acquired during her chemotherapy experience. The woman's adherence to chemotherapy was assessed at the second time point via a medical chart review. Contact of the participant was approved by an institutional review board, so if the principal investigator was unable to meet the participant at the end of her chemotherapy treatments, the participant was contacted and asked permission to mail the last set of questionnaires along with a self-addressed stamped envelope.
Statistical Analysis
The Statistical Package for the Social Sciences 19.0 38 was used for data analysis. Double entry and double-checking were performed to decrease data entry errors. Data analyses consisted of descriptive statistics, correlations, and regression coefficients. Descriptive statistics such as means, frequencies, and standard deviations were used to examine the sample's demographic data. Univariate analysis was performed with # 2 and Fisher exact probability for categorical variables and Student t test for continuous variables. Significant variables were inputted in a model using logistic regressions to predict adherence to treatment. An ! level of .05 was selected as the statistical criterion for significance.
n Results
Adherence to Chemotherapy
Ninety percent (n = 84) of the sample was adherent to their chemotherapy regimen and 10% (n = 9) of the sample discontinued chemotherapy before completion. For the 44 white participants, 87.5% (n = 42) were adherent and 4.3% (n = 2) were nonadherent. For the 49 African American participants, 82.4% (n = 42) were adherent and 13.7% (n = 7) were nonadherent. No racial difference was found in adherence to chemotherapy between African American and white women (# 2 = 2.627, P = .10).
The sample was grouped into 100% adherent (n = 79) and less than 100% adherent (n = 19) groups for further statistical analysis. Between these 2 groups, those who were less than 100% adherent to chemotherapy regimens reported lower income (P G .001). Approximately 66% of those who were 100% adherent had private health insurance or a combination of private insurance and Medicare, whereas only 3% of the women who were less than 100% adherent reported private or combination health insurance (P G .001). For access to transportation to and from treatment sessions, 71% of those who were 100% adherent reported reliable access all the time, whereas 11% of women who were less than 100% adherent reported reliable transportation all the time (P = .016).
Psychosocial Variables
Women who were less than 100% adherent had a higher mean (SD) depression score on the CES-D (12.71 [9. 62]) at the end of end of their chemotherapy (T2) than did those who were 100% adherent (20.62 [10.69]; P = .009). No significant difference in depression scores was found at baseline. In addition, the less than 100% adherent group had a higher fatalistic view of cancer than the 100% adherent group did (4.76 [3.23] 
Knowledge and Health Beliefs
Women who were 100% adherent to chemotherapy were more knowledgeable about general breast cancer facts. The mean (SD) score for this group was 8.72 (1.43) compared with 7.54 (1.71) for women who were less than 100% adherent (P = .01). Using CHBMS, results show that women who were 100% adherent also reported higher motivation to maintain their health (32 [5.51] ) than did women who were less than 100% adherent (26.24 [6.05], P G .001).
Symptom Experiences
Women who were less than 100% adherent reported experiencing more symptoms and more severe symptoms than did women who were 100% adherent. Women who were less than 100% adherent experienced a mean (SD) of 17.33 (6.54) symptoms, whereas the adherent group reported a mean (SD) of 12.94 (5.65) symptoms (P = .018). The mean (SD) severity score for women who were less than 100% adherent was 50.77 (20.22 ) and 31.32 (16.10) for women who were 100% adherent (P G .001).
Days From Diagnosis to Treatment
The exploration of the variable days from diagnosis to treatment (delays to treatment) as a proxy for adherence to treatment recommendations revealed meaningful outcomes. The number of days from diagnosis to treatment in the overall sample ranged from 7 to 564 days. A participant who delayed treatment for more than 500 days did not return to start chemotherapy and was omitted from the analysis. The mean days from diagnosis to treatment was 59.69 days, and delays ranged from 44 to 74 days. The median days to treatment was 42 days and ranged from 35 to 48 days. Women who were less than 100% adherent were more likely to delay starting chemotherapy. The mean (SD) number of days from diagnosis to treatment in the less than 100% adherent group was 100.53 (96.07) days versus 45.96 (36.68) days in the adherent group (P = .041).
Multivariate Analysis
Variables that were significant at P G .10 in the univariate analysis were included for a more robust selection into the multivariate model to predict nonadherence (G100%) to chemotherapy. Bivariate analysis revealed that health insurance and income were highly correlated; thus, income was not included for selection into the final model (r = 0.664, P = .000). Health insurance (odds ratio [OR], 0.071; P = .001), days to treatment (OR, 0.980; P = .028), depression score at T1 (OR, 0.938; P = .083), change in depression score (OR, 0.923; P = .023), Powe's fatalism inventory score (OR, 0.827; P = .050), curability knowledge (OR, 1.75; P = .072), health motivation (OR, 1.20; P = .001), and symptom severity (OR, 0.915; P = .000) were entered into the logistic model and met the criteria (P G .10) for inclusion in the initial adjusted logistic regression model. Using backward stepwise approach, the final model revealed that days to treatment (OR, 0.982; P = .058), health insurance (OR, 0.121; P = .016), change in depression (OR, 0.935; P = .118), and symptom severity (OR, 0.950; P = .038) were independently associated with nonadherence to chemotherapy ( Table 2 ).
n Discussion
The study did not confirm racial differences in rates of nonadherence to recommended chemotherapy regimens. In fact, 90% of the sample was adherent to their chemotherapy, which could indicate a selection bias where highly motivated individuals who were more likely to adhere to treatment consented to be in the study. This study is consistent with other studies where no racial difference in chemotherapy adherence was found. Andic et al 11 found no difference by race in the completion of neoadjuvant chemotherapy for inflammatory breast cancer (whites, 84%; and African Americans, 86.7%) and no difference in the median length of time to completion of treatment (whites, 263 days; and African American, 262 days). Libscomb et al 39 did not find that African American women with breast cancer living in the rural South were more likely to discontinue chemotherapy. In fact, African Americans completed chemotherapy at rates that equal or exceeded those of their white counterparts. 39 The study found that once a woman started chemotherapy, she completed treatment as recommended by her healthcare providers. However, some women experienced considerably more delays from diagnosis to treatment. A longer time to starting treatment after diagnosis was revealed to be a predictor for treatment nonadherence. The median start day was 42 days (range, 7Y564 days), where women who were less than 100% adherent were more likely to have experienced treatment delays. Hershman et al 7 found that 60% of their sample (n = 344) experienced treatment delays in excess of 7 days receiving chemotherapy for early-stage breast cancer, but the study did not test if treatment delays influenced adherence to treatment. Thus, our findings suggest that it is important to acknowledge that the decisionmaking process for adherence starts at the diagnosis of breast cancer. Previous studies defined treatment delay as the time from which a woman finds an abnormality to the time she seeks medical attention. The study is unique where it examined the time period between diagnosis and initiating treatment. Therefore, this finding reveals another important and vulnerable time period to intervene to potentially decrease treatment delay and maximize breast cancer outcomes. Vigorous follow-up could potentially lessen delays and can play a role in improving adequate follow-up to treatment.
Inadequate access to healthcare (ie health insurance) served as a barrier to completing 100% treatment in this sample. Participants who were not covered by private insurance or combination insurance (private plus Medicare) were more likely to complete less than 100% of their treatment. Several other studies have found that health insurance predicts breast cancer outcomes; patients who are uninsured or covered by Medicare or Medicaid are less likely to be screened with mammography, more likely to delay treatment and be diagnosed at more advanced stage of breast cancer, and have decreased survival rates. 40Y42 Systematic interventions can improve the delivery of healthcare, where policies can be implemented to allow equal access to healthcare and treatment. Participants who became depressed during treatment or experienced an increase in depression symptomology (change in depression scores) were more likely to not complete 100% of treatment. However, depression at baseline and depression at the end of treatment were not predictors of treatment adherence. Depression can impact cognitive processes and have an effect on patients' knowledge and understanding of their cancer treatment. 43 Emotional distress has been found to interfere with processing accurate information, where forgetfulness regarding medical information is increased. 43 It is important to recognize the impact that depression has on treatment decision making, where depression compromises physical, emotional, and cognitive functioning, which contributes to ineffective coping, proper cognitive processing of information, maladaptive health beliefs, and finally, delays to starting treatment. It is possible that the proper assessment and treatment of depression can improve clinical outcomes and can help women cope with the breast cancer experience and improve quality treatment decision making.
Intravenous chemotherapy improves survival rates, but not without adverse physical and emotional effects. This study found symptom severity to be an independent predictor of chemotherapy completion. The mean severity score for this sample was 33.9, where participants rated hair loss, lack of energy, difficulty swallowing, changes in the way food tastes, and numbness or tingling in hands and feet as the most severe symptoms. Other studies have found that depression, pain, fatigue, and hair loss are the most common distressing adverse effects experienced by women treated with intravenous treatment for breast cancer. 44, 45 These adverse effects threaten functioning, wellbeing, and quality of life. 44Y48 Distressing physical symptoms can have a significant influence on long-term treatment decisions. 49 Several studies found adverse effects to be the most frequently reported reason for early discontinuation for women taking oral hormonal chemotherapy. 50Y52 Patients will alter their treatment not recommended by their healthcare provider to increase coping and to ameliorate symptoms. 53 Thus, it is important for healthcare providers to assess symptoms and to provide the proper management and treatment to help ameliorate symptom burden. Proper symptom management can increase coping and quality of life and may increase the likelihood to adhere to recommended treatment recommendations.
Limitations
The first limitation to this study was that adherence to intravenous chemotherapy was generally high in this sample, which is clinically advantageous but statistically problematic when exploring relationships and differences in chemotherapy adherence between groups. Second, the study had to change the 85% cut point for statistical analysis, which was a change from the original protocol. In addition, the sample included a convenience sample with an extensive inclusion and exclusion criteria; thus, findings cannot be generalized to the general populations. The study included only women who were diagnosed with early-stage breast cancer because the decision-making process for breast cancer that is still curable is suspected to be different from more advanced breast cancer. Lastly, the final model excluded 26 cases because of missing data, which may overestimate or underestimate the final results.
Conclusions
The strengths of this study and the potential implications of the study's findings are beneficial to the current body of cancer nursing literature. Previous studies used large national databases to assess adherence rates between racial groups. The use of large national databases present with limitations such as difficulty to control for extraneous factors or determine specific predictors of treatment decision making. The study identified delay to treatment, health insurance, depression, and symptom severity as predictors of starting chemotherapy that can be potentially modified with interventions at the clinical setting. In addition, the findings can be used to spearhead future research such as intervention studies that improve treatment decision making to adherence to treatment recommendations.
